Author Correction: ERV1 Overexpression in Myeloid Cells Protects against High Fat Diet Induced Obesity and Glucose Intolerance

Abstract

ERV1tg mice on NCD or HFD for 18 weeks. (j,k) Representative micrographs of liver (j) and VAT (k) stained with hematoxylin and eosin, and Masson's trichrome (k, Bottom row; arrows indicate collagen). (l,n) Weights of livers (l) and single epididymal VAT (n) of WT and ERV1tg mice on NCD or HFD for 18 weeks (n = 4 mice/ group, *P < 0.05 HFD vs. NCD, t test). (m) Fat droplet size in liver of WT and ERV1tg mice on HFD for 18 weeks (n = 4 mice per group, *P < 0.05, t test). (o) Adipocyte size in VAT of mice on HFD or NCD (n = 4 per mice group, *P < 0.05 t tests). All t tests were unpaired and two tailed. Histograms represent mean ± SEM.

Specialized Proresolving Mediators for Therapeutic Interventions Targeting Metabolic and Inflammatory Disorders

“…(2018) demonstrated that ERV1 reduced body weight and provided protection against HFD-induced hyperglycemia. In addition, the administration of RvE1 reproduced the protective effects of ERV1 overexpression ( Sima et al ., 2018 ). In the same mouse model, endogenous production of SPMs such as RvD1, RvD4, RvD5, PD1, and LXA4 increased, indicating a significant contribution of ERV1 receptor signaling to the regulation of SPM production.…”

“…Moreover, the fasting glucose or insulin levels in RvE1 receptor (resolvin E1 receptor [ERV1]/ChemR23) knockout mice were not recovered by RvE1 treatment ( Pal et al ., 2020 ). Using transgenic mice that overexpressed human ERV1 in myeloid cells, Sima et al . (2018) demonstrated that ERV1 reduced body weight and provided protection against HFD-induced hyperglycemia.…”

Understanding resolution of inflammation in periodontal diseases: Is chronic inflammatory periodontitis a failure to resolve?

“…21 Specialized pro-resolving lipid mediators regulate macrophage phenotype favoring pro-healing (M2like) over pro-inflammatory (M1-like) macrophage activation. 34 Resolution pharmacology, as defined by Perretti et al 8…”

“…21 Specialized pro-resolving lipid mediators regulate macrophage phenotype favoring pro-healing (M2like) over pro-inflammatory (M1-like) macrophage activation. 34 Resolution pharmacology, as defined by Perretti et al 8 and Serhan, 35 is different to traditional anti-inflammatory approaches because specialized pro-resolving lipid mediators are receptor agonists. Thus, prolonged contact with the target and maintaining blood levels is not required, as it is the case with inhibitors or receptor antagonists.…”

“…Mediators of inflammation resolution have actions beyond control of white blood cell function; they exhibit receptor‐mediated control of osteoclasts, as well as stem cells that differentiate into fibroblasts and osteoblasts, which play central roles in wound healing and bone regeneration . Specialized pro‐resolving lipid mediators regulate macrophage phenotype favoring pro‐healing (M2‐like) over pro‐inflammatory (M1‐like) macrophage activation …”